General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis

Article

March 5, 2008

DermTech adds Allan C. Halpern, M.D., to company's melanoma advisory board

Biotechnology company DermTech announced the addition of Allan C. Halpern, M.D., chief of dermatology at Memorial Sloan-Kettering Cancer Center, to its melanoma advisory board, according to The Earth Times.

La Jolla, Calif.

- Biotechnology company DermTech announced the addition of Allan C. Halpern, M.D., chief of dermatology at Memorial Sloan-Kettering Cancer Center, to its melanoma advisory board, according to The Earth Times.

DermTech is developing molecular diagnostics for the early detection of melanoma and other diseases. Dr. Halpern is a widely recognized expert in the early detection and management of melanoma in high-risk patients, the Times reports.